Tag: $Gilead Sciences

Gilead Sciences agrees to acquire biotech company Arcellx for $7.8 billion.

Gilead Sciences (GILD) reported its fourth-quarter and full-year 2025 financial results on February 10, 2026, highlighting strong performance in its base business despite competitive pressures in certain segments. The company’s stock declined 0.94% in aftermarket trading to $150.26, despite exceeding analyst expectations for both revenue and earnings.

The biotech Gilead Sciences has been the best-performing healthcare stock in the S&P 500 by far over the past 12 months. Its latest financial results late Thursday should reinforce its position

The biotech Gilead Sciences raised its earnings guidance Thursday while reporting second quarter results that beat Wall Street expectations, as the company continues to battle back from an early-year slump in its share price.

Gilead GILD +0.57% Sciences recently spent about $30 million to increase its stakes in two biotech stocks.

Gilead Sciences has received a positive response from the European Medicines Agency’s Committee for Medicinal Products for Human Use on an additional indication for the use of its antibody-drug conjugate Trodelvy in certain types of pre-treated breast cancer.